Last updated: May 26, 2026
What is the current clinical trial status for hydrocodone polistirex and chlorpheniramine polistirex?
No complete, current clinical trials dataset is available in the provided materials to support an accurate “status update” (trial identifiers, sponsors, enrollment, primary endpoints, recruitment status, or results). Without verifiable trial records, a trial-level update would not be actionable.
What to look for in registries (but not supplied here)
- ClinicalTrials.gov listing(s) for “hydrocodone polistirex,” “chlorpheniramine polistirex,” and the combination
- Record fields: phase, start/completion dates, recruitment status, NCT numbers, outcomes, and results posted dates
- Sponsor and comparator arms (standard hydrocodone/chlorpheniramine immediate-release vs extended-release polistirex)
How big is the market for hydrocodone polistirex and chlorpheniramine polistirex?
No market sizing inputs are provided (historical US sales, TRx/units, pricing, share, payer mix, channel distribution, or utilization trends). Without those, market analysis cannot be produced with the required precision.
What typically drives demand for this product class
- Indication scope for combination antitussive with sedating antihistamine
- Extended-release benefit vs immediate-release cough/cold products
- Regulatory and payer restrictions tied to opioid-containing antitussives
- Substitution pressure from non-opioid cough suppressants and antihistamine-only products
When will hydrocodone polistirex and chlorpheniramine polistirex revenue peak or decline?
No exclusivity, patent, or launch/phase-out timeline data is provided to support a defensible projection.
What governs the projection (not supplied)
- Orange Book status (active ingredient: hydrocodone bitartrate for US listings; polistirex forms)
- Remaining patent term for composition, formulation, and extended-release mechanisms
- FDA labeling transitions and Risk Evaluation and Mitigation Strategy (REMS) status, if applicable
- Generic and authorized generic entry windows
- Actual product discontinuations or supply constraints
What is the FDA regulatory status of hydrocodone polistirex and chlorpheniramine polistirex?
No FDA product-specific regulatory record is provided (NDA/BLA number, approval date, current labeling, REMS requirements, or Orange Book listings). A current regulatory summary would require those identifiers.
What should be extracted from FDA sources (not supplied here)
- Drug approval reference listed drug (RLD) name and application number
- Current dosage form strength, recommended age limits, and warnings
- Changes to Boxed Warning or opioid-related labeling
- Labeling for antihistamine sedation and anticholinergic risk
What patents protect hydrocodone polistirex and chlorpheniramine polistirex, and when do they expire?
No patent estate data is provided, so patent protection and expiration cannot be listed.
What patent analytics usually include (not supplied)
- Composition-of-matter claims (polistirex matrix and drug loading)
- Controlled-release mechanism claims (ion-exchange/complex formation)
- Method-of-manufacture claims for the polistirex formulation
- Method-of-use claims aligned to cough suppression and antihistamine effects
- Orange Book-listed patent numbers and expiration dates
How strong is the patent estate for hydrocodone polistirex and chlorpheniramine polistirex versus generic entry risk?
No claim-level or Orange Book patent listing information is provided, so strength scoring and generic entry risk cannot be calculated.
What affects generic risk (not supplied)
- Whether the key patents are formulation (harder design-around) vs manufacturing (process-specific)
- Whether the RLD is listed with multiple protections (tech transfer and bioequivalence hurdles)
- Whether there are documented Paragraph IV challenges (litigation record)
Have any Paragraph IV challenges been filed for hydrocodone polistirex and chlorpheniramine polistirex?
No litigation/PIV record is provided, so it is not possible to report filings, outcomes, or settlement terms.
What would be required for a litigation-based projection (not supplied)
- ANDA number(s), applicant(s), filing dates
- Certification type (Paragraph IV vs I vs II etc.)
- Case docket numbers and district court jurisdictions
- Settlement agreement dates and trigger dates for generic entry
What clinical endpoints would matter most for updated trials in this combination product?
No current trial dataset is provided, so endpoint selection can’t be mapped to the actual program.
Typical endpoints for combination antitussives in extended-release products
- Cough frequency reduction over defined periods
- Symptom score changes (daytime and nighttime cough)
- Time to onset of effect and duration of action
- Safety endpoints: CNS depression, somnolence, anticholinergic effects
- Abuse/misuse risk signals for opioid-containing formulations
How does hydrocodone polistirex and chlorpheniramine polistirex compare with alternatives in the cough/cold market?
No competitor list, market share, or pricing data is provided, so a meaningful comparative analysis cannot be produced.
Likely comparators (need verification, not supplied)
- Immediate-release hydrocodone combination antitussives (where available)
- Non-opioid antitussives (e.g., dextromethorphan formulations)
- Antihistamine-only extended-release syrups and tablets
- Combination products with different opioid or non-opioid actives
Key Takeaways
- A clinical trials update for hydrocodone polistirex and chlorpheniramine polistirex cannot be delivered without verifiable trial records (NCT-level details and current statuses).
- A market analysis and revenue projection cannot be produced without product-level historical sales/utilization and regulatory/patent or exclusivity inputs.
- The required market and IP drivers (FDA status, Orange Book listings, patent expirations, Paragraph IV/litigation events, and competitive entry) are not included in the provided materials.
FAQs
1) What is the approved indication and dosing for hydrocodone polistirex and chlorpheniramine polistirex?
Not provided.
2) Are there ongoing or recently completed clinical trials for hydrocodone polistirex and chlorpheniramine polistirex?
Not provided.
3) What is the Orange Book status of hydrocodone polistirex and chlorpheniramine polistirex?
Not provided.
4) What generic entry risks exist for this combination product in the US?
Not provided.
5) What are the most likely alternative products affecting demand for this drug?
Not provided.
References (APA)
No cited sources were provided in the input.
